Updated Jul 16, 2026
Hassan Fred has filed 1 SEC Form 4 filing across 1 company in the last 90 days.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-24 | BBIO | BridgeBio Pharma, Inc. | A — Grant or award | 4.0K | $0.00 | |
| 2026-03-16 | PGEN | PRECIGEN, INC. | M — Option exercise | 71.8K | — | |
| 2026-03-12 | PGEN | PRECIGEN, INC. | A — Grant or award | 17.9K | $3.51 | $63K |
| 2025-10-30 | COCP | Cocrystal Pharma, Inc. | A — Grant or award | 359.7K | $1.39 | $500K |
| 2025-06-20 | BBIO | BridgeBio Pharma, Inc. | A — Grant or award | 6.6K | $0.00 | |
| 2024-10-11 | COCP | Cocrystal Pharma, Inc. | A — Grant or award | 8.1K | — |
Hassan Fred is a corporate insider — currently tracked as Director of BridgeBio Pharma, Inc. (BBIO). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Hassan Fred profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.